Literature DB >> 26248361

Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.

Robert Bucki1, Katarzyna Niemirowicz2, Urszula Wnorowska2, Fitzroy J Byfield3, Ewelina Piktel2, Marzena Wątek4, Paul A Janmey3, Paul B Savage5.   

Abstract

Ceragenins constitute a novel family of cationic antibiotics characterized by a broad spectrum of antimicrobial activities, which have mostly been assessed in vitro. Using a polarized human lung epithelial cell culture system, we evaluated the antibacterial activities of the ceragenin CSA-13 against two strains of Pseudomonas aeruginosa (PAO1 and Xen5). Additionally, the biodistribution and bactericidal activity of a CSA-13-IRDye 800CW derivate were assessed using an animal model of peritoneal infection after PAO1 challenge. In cell culture, CSA-13 bactericidal activities against PAO1 and Xen5 were higher than the activities of the human cathelicidin peptide LL-37. Increased CSA-13 activity was observed in polarized human lung epithelial cell cultures subjected to butyric acid treatment, which is known to increase endogenous LL-37 production. Eight hours after intravenous or intraperitoneal injection, the greatest CSA-13-IRDye 800CW accumulation was observed in mouse liver and kidneys. CSA-13-IRDye 800CW administration resulted in decreased bacterial outgrowth from abdominal fluid collected from animals subjected to intraperitoneal PAO1 infection. These observations indicate that CSA-13 may synergistically interact with antibacterial factors that are naturally present at mucosal surfaces and it maintains its antibacterial activity in the infected abdominal cavity. Cationic lipids such as CSA-13 represent excellent candidates for the development of new antibacterial compounds.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26248361      PMCID: PMC4576122          DOI: 10.1128/AAC.00653-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  Development of a broad spectrum polymer-released antimicrobial coating for the prevention of resistant strain bacterial infections.

Authors:  K D Sinclair; T X Pham; R W Farnsworth; D L Williams; C Loc-Carrillo; L A Horne; S H Ingebretsen; R D Bloebaum
Journal:  J Biomed Mater Res A       Date:  2012-05-24       Impact factor: 4.396

2.  In vitro evaluation of the potential for resistance development to ceragenin CSA-13.

Authors:  Jake E Pollard; Jason Snarr; Vinod Chaudhary; Jacob D Jennings; Hannah Shaw; Bobbie Christiansen; Jonathan Wright; Wenyi Jia; Russell E Bishop; Paul B Savage
Journal:  J Antimicrob Chemother       Date:  2012-08-16       Impact factor: 5.790

3.  Effect of pluronic acid F-127 on the toxicity towards eukaryotic cells of CSA-13, a cationic steroid analogue of antimicrobial peptides.

Authors:  C Nagant; P B Savage; J P Dehaye
Journal:  J Appl Microbiol       Date:  2012-04-20       Impact factor: 3.772

4.  Effect of a low concentration of a cationic steroid antibiotic (CSA-13) on the formation of a biofilm by Pseudomonas aeruginosa.

Authors:  C Nagant; Y Feng; B Lucas; K Braeckmans; P Savage; J P Dehaye
Journal:  J Appl Microbiol       Date:  2011-07-20       Impact factor: 3.772

5.  Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells.

Authors:  Kengo Kuroda; Tomokazu Fukuda; Kazuhiko Okumura; Hiroshi Yoneyama; Hiroshi Isogai; Paul B Savage; Emiko Isogai
Journal:  Anticancer Drugs       Date:  2013-09       Impact factor: 2.248

6.  Characterization of a novel active release coating to prevent biofilm implant-related infections.

Authors:  Dustin L Williams; Kristofer D Sinclair; Sujee Jeyapalina; Roy D Bloebaum
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2013-04-04       Impact factor: 3.368

7.  Efficacy of a synthetic antimicrobial peptidomimetic versus vancomycin in a Staphylococcus epidermidis device-related murine peritonitis model.

Authors:  Jorunn Pauline Cavanagh; Hildegunn Norbakken Granslo; Elizabeth Aarag Fredheim; Lars Christophersen; Peter Østrup Jensen; Kim Thomsen; Maria Van Gennip; Claus Klingenberg; Trond Flaegstad; Claus Moser
Journal:  J Antimicrob Chemother       Date:  2013-05-03       Impact factor: 5.790

8.  Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections.

Authors:  Katarzyna Leszczynska; Dorota Namiot; Fitzroy J Byfield; Katrina Cruz; Malgorzata Zendzian-Piotrowska; David E Fein; Paul B Savage; Scott Diamond; Christopher A McCulloch; Paul A Janmey; Robert Bucki
Journal:  J Antimicrob Chemother       Date:  2012-11-07       Impact factor: 5.790

9.  Study of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa.

Authors:  Carole Nagant; Betsey Pitts; Philip S Stewart; Yanshu Feng; Paul B Savage; Jean-Paul Dehaye
Journal:  Microbiologyopen       Date:  2013-02-25       Impact factor: 3.139

10.  D-alanylation of lipoteichoic acids confers resistance to cationic peptides in group B streptococcus by increasing the cell wall density.

Authors:  Ron Saar-Dover; Arkadi Bitler; Ravit Nezer; Liraz Shmuel-Galia; Arnaud Firon; Eyal Shimoni; Patrick Trieu-Cuot; Yechiel Shai
Journal:  PLoS Pathog       Date:  2012-09-06       Impact factor: 6.823

View more
  16 in total

Review 1.  Emerging and future strategies in the management of recalcitrant Candida auris.

Authors:  Nihal Bandara; Lakshman Samaranayake
Journal:  Med Mycol       Date:  2022-03-17       Impact factor: 4.076

2.  LEGO-Lipophosphonoxins: A Novel Approach in Designing Membrane Targeting Antimicrobials.

Authors:  Duy Dinh Do Pham; Viktor Mojr; Michaela Helusová; Gabriela Mikušová; Radek Pohl; Eva Dávidová; Hana Šanderová; Dragana Vítovská; Kateřina Bogdanová; Renata Večeřová; Miroslava Htoutou Sedláková; Radovan Fišer; Petra Sudzinová; Jiří Pospíšil; Oldřich Benada; Tomáš Křížek; Adéla Galandáková; Milan Kolář; Libor Krásný; Dominik Rejman
Journal:  J Med Chem       Date:  2022-07-15       Impact factor: 8.039

3.  Bactericidal Activity of Ceragenin in Combination with Ceftazidime, Levofloxacin, Co-Trimoxazole, and Colistin against the Opportunistic Pathogen Stenotrophomonas maltophilia.

Authors:  Paulina Paprocka; Angelika Mańkowska; Karol Skłodowski; Grzegorz Król; Tomasz Wollny; Agata Lesiak; Katarzyna Głuszek; Paul B Savage; Bonita Durnaś; Robert Bucki
Journal:  Pathogens       Date:  2022-05-26

Review 4.  Beyond conventional antibiotics - New directions for combination products to combat biofilm.

Authors:  Danir Fanisovich Bayramov; Jennifer Ann Neff
Journal:  Adv Drug Deliv Rev       Date:  2016-08-03       Impact factor: 15.470

5.  CSA-90 Promotes Bone Formation and Mitigates Methicillin-resistant Staphylococcus aureus Infection in a Rat Open Fracture Model.

Authors:  Rebecca Mills; Tegan L Cheng; Kathy Mikulec; Lauren Peacock; David Isaacs; Carl Genberg; Paul B Savage; David G Little; Aaron Schindeler
Journal:  Clin Orthop Relat Res       Date:  2018-06       Impact factor: 4.176

6.  Antibacterial and Antibiofilm Activities of Ceragenins against Pseudomonas aeruginosa Clinical Isolates.

Authors:  Çağla Bozkurt Güzel; Mayram Hacioğlu; Gözde Inci; Paul B Savage
Journal:  Turk J Pharm Sci       Date:  2019-11-11

7.  CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway.

Authors:  Chunlan Xu; Sally Ghali; Jiani Wang; David Q Shih; Christina Ortiz; Caroline C Mussatto; Elaine C Lee; Diana H Tran; Jonathan P Jacobs; Venu Lagishetty; Phillip Fleshner; Lori Robbins; Michelle Vu; Tressia C Hing; Dermot P B McGovern; Hon Wai Koon
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

8.  Antimicrobial ceragenins inhibit biofilms and affect mammalian cell viability and migration in vitro.

Authors:  Melissa A Olekson; Tao You; Paul B Savage; Kai P Leung
Journal:  FEBS Open Bio       Date:  2017-05-22       Impact factor: 2.693

Review 9.  Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.

Authors:  Ewelina Piktel; Katarzyna Niemirowicz; Marzena Wątek; Tomasz Wollny; Piotr Deptuła; Robert Bucki
Journal:  J Nanobiotechnology       Date:  2016-05-26       Impact factor: 10.435

10.  Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13.

Authors:  Katarzyna Niemirowicz; Bonita Durnaś; Grażyna Tokajuk; Ewelina Piktel; Grzegorz Michalak; Xiaobo Gu; Alina Kułakowska; Paul B Savage; Robert Bucki
Journal:  Sci Rep       Date:  2017-07-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.